Global Wellness’ Shanti Therapeutics Boosts Team with International Advisors

The Shanti Therapeutics Focus on Chronic Pain Market with Psychedelics

Vancouver, British Columbia, February 18, 2022 – Global Wellness Strategies Inc. (CSE: GWS) (Frankfurt:O3X4) (OTCQB: GWSFF) (“Global” or the “Company”) today announced the addition of two International Pedigreed Senior Advisors to its team and the appointment of Meris Kott to the board of Shanti Therapeutics. Shanti Therapeutics is focused on finding a solution to chronic pain with Psychedelics using MDMA.

“As we engage in our largest capital raise to date, our bolstered team of advisers is pivotal to our success. They put us in a stronger position as we continue to disrupt the status quo of the psychedelic sector with our focus on finding a solution to the unmet needs of the chronic pain epidemic. We are eager to introduce Shanti to the biotech investment community globally to join our current shareholders as investors. I am delighted to join the Shanti team and to help change the puzzle of pain landscape together with them.” said Meris Kott, CEO, Global Wellness Strategies Inc.

Global Wellness Strategies’ advisory hires across pharma, product and business development, investment banking and sales are in place to support Shanti Therapeutics as a first-in-class biotech utilizing the neuromodulation properties of MDMA (aka Ecstasy) to pre-emptively treat preoperative pain. Shanti has commenced a path to their clinical trial in 22 healthy volunteers comparing the pain tolerance threshold in patients who have had exposure to a proprietary dose and formulation of MDMA. This proof-of-concept clinical study is to gauge the effect size of an increase in the pain threshold in subjects who have been pre-emptively treated with MDMA.

Advisory Team Strengthened with Diverse International Experience

Darryl Davies (B.Sc.) is a global leader and a founder of Shanti Therapeutics and has over 15 years experience in healthcare and in the medicinal cannabis industry with a strong background in psychology, harm minimization and medicinal cannabis regulatory. He has facilitated and executed meaningful relationships with public and private global cannabis licensed producers, biotech, and research institutions. He coordinated the execution of Australia’s first leadership program for the cannabis industry in partnership with Deakin University and the University of Western Sydney. He is the co-founder of private Australian award-winning cannabis company, Cannvalate, specializing in the late part of the cannabis value chain; appointed Australia’s only Director for Canadian manufacturing powerhouse, The Valens Company (TSX: VLNS); Director of New Zealand’s Greenfern Industries Ltd (NZE: GFI); and Australia’s InhaleRx Ltd. (ASX:IRX) .

Shiry Eden (MBA) is CEO and Founder at NISHOT, a strategy and analysis firm focusing on the global cannabis and psychedelic industries. In 2022 she founded the Israeli cannabis and psychedelic magazine “Cannabis Capital”. Since 2018, Shiry is a partner in an Israeli-global oriented mutual fund “SELA CANNABIS”. She has over 20 years of experience as an economist and strategic advisor for medium to large-scale corporates in Israel, with expertise in the capital market. Prior to the establishment of Nishot, she founded and managed Eden Communications and LivingGift, served as a corporate communications manager in the second largest investment house in Israel, media advisor for the Minister of Defense, and an economist in the Budget Department of the Ministry of Defense. Shiry holds a BA in Economics and Communications from the Hebrew University and an MBA from Tel Aviv University.


About Global Wellness Strategies

Global Wellness Strategies is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast-growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies.

For further information visit websites: and

Or Contact Meris Kott CEO 604.484.0355 or email to [email protected]

Further information about the Company is available on under the Company’s profile.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute “forward–looking statements” or “forward-looking information” (collectively “forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, its financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.